Of note, in a study assessing efficacy and safety of Maraviroc showed slightly increased CD4 counts through 9 months of treatment and appeared to increase naïve CD8+ T cells in the digestive tract, highlighting the potential benefit of restoring immune function by targeting infection-associated inflammation in lymphoid tissues (111). Here, CD4 is linked to infection.